Rallybio (FRA:33M0) Total Receivables: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:33M0 Rallybio Corp FRA:33M0
18 GF Score
Price €13.90
! 5 Warning Signs
View Full Analysis

What is Rallybio Total Receivables?

Rallybio FRA:33M0 -1.42% 18 Total Receivables is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:33M0 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Rallybio's Total Receivables for the quarter that ended in Mar. 2026 was €0.00 Mil.

Rallybio Total Receivables Historical Data

* Premium members only.

The historical data trend for Rallybio's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rallybio Total Receivables Chart

Rallybio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Rallybio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:33M0
18GF Score
Rallybio Corp FRA:33M0
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rallybio Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.00 Mil mean?
Rallybio (FRA:33M0) has a Total Receivables of €0.00 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Rallybio and its competitors.
Is Rallybio's Total Receivables too high?
Rallybio's current Total Receivables is €0.00 Mil. Overall, Rallybio has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rallybio's Total Receivables compare to VRCA and HRTX?
Rallybio's Total Receivables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Rallybio and its competitors. Rallybio's current Total Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rallybio stock overvalued right now?
Rallybio (FRA:33M0) has a current Total Receivables of €0.00 Mil. The current Total Receivables is €0.00 Mil. Rallybio's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Rallybio (FRA:33M0), the current Total Receivables is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rallybio Business Description

Other Exchanges RLYB:USA
Address 234 Church Street, Suite 1020, New Haven, CT, USA, 06510
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
18GF Score

Get the complete analysis for FRA:33M0

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.90
Price